p62 is a useful predictive marker for tumour regression after chemoradiation therapy in patients with advanced rectal cancer: an immunohistochemical study.
Toshinori KobayashiMitsuaki IshidaHisanori MikiYuki MatsumiToshiro FukuiMadoka HamadaKoji TsutaMitsugu SekimotoPublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2021)
A higher p62 expression score was significantly associated with less CRT effectiveness in patients with advanced rectal cancer. Analysis of p62 expression score using biopsy specimens is a useful and easily assessable prediction marker for CRT effect and might help select patients who can undergo a 'watch-and-wait' strategy after CRT.